ALTAO
Research ALTAO on Bullrun: market cap EUR 19.96M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALTAO
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 19.96M
- Financial periodFY2025
- RevenueEUR 661.00K
- Revenue growth7.7%
- Net income-EUR 962.00K
- Free cash flowEUR 142.00K
- Gross margin74.3%
Valuation Snapshot
latest market cap is EUR 19.96M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 661.00K | -EUR 962.00K | EUR 142.00K | 74.3% | 0 | EUR 455.00K | EUR 4.95M | EUR 37.00K |
| FY2024 | EUR 614.00K | -EUR 1.10M | EUR 28.00K | 80.0% | 0 | EUR 84.00K | EUR 4.65M | EUR 791.00K |
| FY2023 | EUR 612.00K | -EUR 7.87M | -EUR 3.58M | 73.2% | -0.03 | EUR 111.00K | EUR 6.88M | -EUR 2.10M |
| FY2022 | EUR 1.57K | -EUR 563.57K | n/a | -13459.9% | 0 | EUR 597.54K | EUR 2.24M | EUR 10.23M |
| FY2021 | EUR 147.13K | -EUR 69.16K | n/a | -74.3% | 0 | EUR 1.54M | EUR 970.89K | EUR 9.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 19.96M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ALTAO
Aton operates as a bioscience company in France. It engages in drug development, preclinical and clinical services, production of monoclonal antibodies, laboratory equipment production, and designing and manufacturing of medical devices, as well as provision of human tissues. The company also offers medical devices for surgeons, powered by Stemcis. The company was founded in 1998 and is headquartered in Strasbourg, France.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ALTAO's market cap?
ALTAO's market capitalization is EUR 19.96M.
What does ALTAO do?
Aton operates as a bioscience company in France. It engages in drug development, preclinical and clinical services, production of monoclonal antibodies, laboratory equipment production, and designing and manufacturing of medical devices, as well as provision of human tissues. The company also offers medical devices for surgeons, powered by Stemcis. The company was founded in 1998 and is headquartered in Strasbourg, France.